BlackRock Fund Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

BlackRock Fund Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$263M	Buy	7,252,632 +7,226,676	+27,842%	+$289M	0.05%	454
2016 Q3	$1.19M	Sell	25,956 -5,607	-18%	-$293K	﹤0.01%	3217
2016 Q2	$1.58M	Buy	31,563 +3,436	+12%	+$183K	﹤0.01%	3227
2016 Q1	$1.5M	Sell	28,127 -12,816	-31%	-$752K	﹤0.01%	3133
2015 Q4	$2.69M	Sell	40,943 -116,446	-74%	-$7.2M	﹤0.01%	3077
2015 Q3	$8.89M	Sell	157,389 -178,900	-53%	-$11.6M	﹤0.01%	2445
2015 Q2	$19.9M	Sell	336,289 -33,350	-9%	-$2.06M	﹤0.01%	2121
2015 Q1	$23M	Buy	369,639 +88,050	+31%	+$5.12M	0.01%	1997
2014 Q4	$16.2M	Buy	281,589 +45,323	+19%	+$2.53M	﹤0.01%	2181
2014 Q3	$12.7M	Buy	236,266 +77,632	+49%	+$4.11M	﹤0.01%	2216
2014 Q2	$8.32M	Buy	158,634 +66,036	+71%	+$3.38M	﹤0.01%	2530
2014 Q1	$4.89M	Buy	92,598 +34,400	+59%	+$1.59M	﹤0.01%	2830
2013 Q4	$2.33M	Buy	58,198 +25,900	+80%	+$1.02M	﹤0.01%	3119
2013 Q3	$1.22M	Buy	32,298 +4,464	+16%	+$174K	﹤0.01%	3164
2013 Q2	$1.09M	Buy	+27,834	New	+$1.08M	﹤0.01%	3151

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

BlackRock Fund Advisors's TEVA Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Teva Pharmaceuticals (TEVA) stake by 27,842% in Q4 2016, buying an estimated $289M and bringing the position to 7,252,632 shares worth $263M. The position accounts for 0.05% of the portfolio, ranked #454.

BlackRock Fund Advisors first reported a position in TEVA in Q2 2013 and has held it in 15 quarters since. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

BlackRock Fund Advisors held 7,252,632 shares of Teva Pharmaceuticals worth $263M as of Q4 2016.
BlackRock Fund Advisors bought 7,226,676 Teva Pharmaceuticals shares in Q4 2016, an estimated $289M.
Teva Pharmaceuticals made up 0.05% of BlackRock Fund Advisors's portfolio in Q4 2016, its #454 holding.
BlackRock Fund Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.